Impurity does not increase cancer risk

摘要

An impurity,ethyl mesilate,found in batches of HIV medicine nelfinavir(Viracept),which resulted in a global recall of the product,does not increase patients'risk of developing cancer,says the European Medicines Agency(EMEA).The EMEA's Committee for Medicinal Products for Human Use confirmed this following research conducted by manufacturer Roche and validated by independent experts.The studies show that patients exposed to the highest levels of the genotoxic impurity received doses that were well below the threshold for DNA damage to occur.